TCRX FY 2023 Earnings — TScan Therapeutics, Inc. Revenue & Financial Results | Market Cap Arena

TCRXTScan Therapeutics, Inc.

$69M

FY 2023 Earnings

Healthcare Biotechnology

Income Statement

Revenue

$21M+55.5% YoY

Gross Profit

$21M100.0% margin

Operating Income

-$93M-444.0% margin

Net Income

-$89M-423.9% margin

EPS (Diluted)

$-1.36

Cash Flow

Operating Cash Flow

-$61M

Free Cash Flow

-$65M

Stock-Based Comp.

$5M

Balance Sheet

Total Assets

$272M

Total Liabilities

$121M

Stockholders' Equity

$151M

Cash & Equivalents

$133M

Year-over-Year Comparison

Metric	Current	Year Ago	Change
Revenue	$21M	$14M	+55.5%
Gross Profit	$21M	$14M	+55.5%
Operating Income	-$93M	-$67M	-40.3%
Net Income	-$89M	-$66M	-34.7%